Objective: Recent improvement of best medical treatment for carotid stenosis has sparked a debate on the role of surgerydidentification of patients who may benefit from carotid endarterectomy (CEA) is crucial to avoid overtreatment. An expected 5-year postoperative survival is one of the main selection criteria. The aim of this study was the development of a score for predicting survival of asymptomatic patients after CEA.
The benefit of carotid endarterectomy (CEA) for the prevention of stroke in patients with severe carotid stenosis was shown in the mid-1990s 1 and later corroborated by larger trials. 2 More recently, the appropriateness of CEA for asymptomatic patients has become a matter of controversy. Results of randomized trials comparing best medical treatment (BMT) alone with BMT plus CEA are now being questioned because BMT has improved its effectiveness through the years. 3, 4 As a result, there is now a lack of univocal consensus on this subject; some surgeons have completely ceased to routinely offer surgical treatment to asymptomatic patients. Contemporary guidelines stress the importance of selection of patients for the treatment of asymptomatic carotid disease. A target of 3 to 5 years of postoperative life expectancy 5, 6 is specifically recommended.
Although there are probably other factors that identify subgroups of patients who will likely profit the most from an aggressive approach (high-risk plaques, patients with hypercoagulable status), we believe that a "selective approach" to asymptomatic stenosis, consisting of offering surgery to those patients who will survive long enough to benefit from surgery, is the easiest way to avoid unnecessary treatments.
The aim of our study was to provide clinicians with a score that could help them stratify patients by their survival likelihood to select the best candidates for CEA for asymptomatic carotid stenosis.
METHODS
We derived our score for postoperative long-term mortality from a retrospective cohort of consecutive This study is in agreement with the principles outlined in the Declaration of Helsinki. Patients gave informed consent for use of personal data to the hospital at which they received medical care, according the Italian state laws; no Institutional Review Board approval or informed consent of the patients was required because this research was a retrospective analysis.
Patients without an ipsilateral or nonhemispheric neurologic event during the previous 6 months were defined as asymptomatic.
Patients who underwent surgery for restenosis and concomitant CEA and coronary artery bypass grafting were excluded from this study. In case of bilateral CEA, survival was calculated from the first procedure. In our division, CEA is always the first treatment option unless there is evidence of a major medical contraindication (congestive heart failure class III/IV, left ventricular ejection fraction <30%, unstable angina, recent myocardial infarction [MI] , chronic obstructive pulmonary disease [COPD] with forced expiratory volume in the first second of expiration <30%) or presence of anatomic risk factors (high lesions, tandem intracranial lesions, presence of a tracheostomy, prior irradiation or surgery to the neck, recurrent stenosis, contralateral laryngeal palsy). Contralateral carotid occlusion is not considered an absolute contraindication. A database of asymptomatic patients who underwent CEA from January 2002 to September 2013 at Ospedale San Carlo Borromeo was used as the primary source for data collection. This database included demographics, comorbidities, medications, and treatment details.
The presence of hypertension, diabetes mellitus (DM), dyslipidemia, and pulmonary disease was recorded in case of a previous specific diagnosis or if the patient was under specific treatment. Kidney function was directly tested during preoperative assessment. Coronary artery disease (CAD) was recorded if the patients had suffered MI or angina or underwent a coronary revascularization with either percutaneous transluminal coronary angioplasty or coronary artery bypass grafting.
Postoperative long-term survival was assessed for each patient. Hospital records of outpatient visits, diagnostic procedures, and rehospitalizations were queried. For patients without recent admission to the hospital, survival was assessed through telephone calls.
Score derivation. Long-term postoperative survival was estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated for several potential risk factors using Cox regression models. For deriving our score, we selected those parameters that showed a statistically significant correlation with survival and those parameters that, despite not reaching significance, have an undisputed clinical relevance for survival. For each of these parameters, we calculated the b coefficient associated with each univariate HR. Comparison among different b coefficients allowed us to "weight" the relative importance of different parameters and therefore to assign an individual score to each of them. A cumulative score was calculated for each patient, allowing us to stratify them. We therefore arbitrarily divided them into four "risk groups" according to their score. Group-specific survival curves were calculated and differences were tested by log-rank test and Wilcoxon test. A P value of .05 was considered significant. Score validation. We validated the score obtained on a different population of asymptomatic patients who underwent CEA in two different medical centers. The two hospitals share the same indications for treating carotid stenosis with the first one (see earlier). The validation cohort (VC) resulted from merging of two series of consecutive patients operated on in both centers before 2010 (5-year followup minimum). Data collection was limited to the parameters of our scoring system to be able to assign a score to each patient. Similar to the derivation cohort (DC), long-term survival was assessed through existing records and, in case of no further contact, through telephone calls. No technical aspect of perioperative management was standardized; anesthesia, type of intraoperative brain monitoring, and type of intraoperative control may have differed among centers. Surgical technique was always left to the surgeon's preference.
ARTICLE HIGHLIGHTS d
Type of Research: Retrospective cohort study d Take Home Message: Based on data of 648 operations, the authors developed a scoring system to predict 5-year survival in patients with asymptomatic carotid artery disease. The scores, based on six factors (age, coronary artery disease, renal function, diabetes mellitus, chronic obstructive pulmonary disease, and statin therapy), were validated on a separate cohort of 334 patients.
The authors recommend using their scoring system to calculate the probability of survival for 5 years in asymptomatic patients with carotid stenosis who may be candidates for carotid intervention.
RESULTS

DC.
Among 648 consecutive asymptomatic patients who underwent CEA in our institution between January 2002 and September 2013, mean age was 73.7 6 7.6 years (range, 47-93 years). Two-thirds were men (429 patients). Preoperative comorbidities and medications are shown in Table I .
Eight patients suffered a 30-day postoperative stroke (1.2%), three minor strokes (National Institutes of Health Stroke Scale score #4) and five moderate to major strokes (National Institutes of Health Stroke Scale score >4). One of these patients died, and this was the only death recorded in the cohort (perioperative mortality of 0.15%). Four patients had an MI (0.6%).
Median follow-up was 56 months (interquartile range, 27-84 months). Estimated survival of the overall cohort was 98.9% 6 0.4% at 1 year, 92.7% 6 1.1% at 3 years, and 84.7% 6 1.7% at 5 years (Fig 1) .
Score derivation. According to the method described in the preceding section, we made a list of factors potentially linked to postoperative mortality and obtained their HRs (Table II) . Six factors were selected among our list to be considered for the score: age, renal status, absence of statins at the time of surgery, CAD, DM, and COPD. Age and renal status being two continuous variables, they were transformed to ordinal variables. Age was split into three classes (<70, 70-80, and >80 years). For renal function, we arbitrarily chose a serum creatinine threshold of 132.6 mmol/L (1.5 mg/dL) to divide the first two classes; patients under dialysis were assigned to the third. For each of the selected factors, a b coefficient was calculated and used to assign a proportional score, using the lowest value as a reference (Table III) . After calculating the total sum for each patient, four different risk groups, with progressive score, were created. Group 1, estimated low risk, consisted of 170 patients (26.2%), for which the score was 0 to 3 points; 299 patients (46.1%) with score ranging from 4 to 7 points belonged to group 2, with an estimated mild risk; with a score of 8 to 11 points, 145 patients (22.4%) composed group 3, at estimated moderate risk; last, group 4, estimated severe risk, was formed by 27 patients (4.2%) with a score of 12 or higher (Table IV) .
To test our stratification, we calculated the survival curves for each group and compared them. The estimated 5-year survival was 96.9% 6 1.5% for group 1, 88.4% 6 2.1% for group 2, 69.6% 6 4.7% for group 3, and 51.4% 6 13.5% for group 4 (P < .0001; Fig 2) . Score validation. Data of 334 consecutive asymptomatic patients who underwent CEA before 2010 at IRCCS Policlinico San Donato and Spedali Civili were collected. Mean age was 72 6 8 years (range, 45-89 years), and 63% were male (210 patients).
Prevalence of the score factors was compared between the two cohorts (Table V) . We observed a higher prevalence of CAD in the VC (30% vs 20%; P < .001) and a lower proportion of patients not taking statin therapy (40% vs 56%; P < .001). Perioperative outcomes were similar to those of the DC: 30-day postoperative stroke rate was 1% vs 1.2% (P ¼ .67), 30-day postoperative MI rate was 0.8% vs 0.6% (P ¼ .63), and 30-day postoperative mortality was 0.3% vs 0.15% (P ¼ .55).
Long-term postoperative survival of the VC was similar to that of the DC with 1-year, 3-year, and 5-year survival rates of 96.7% (vs 98.9%), 91% (vs 92.7%), and 85.2% (vs 84.7%), respectively (P ¼ .41; Fig 1) .
By applying our score to the VC, we stratified the patients into four risk groups. A statistically significant difference was found in the median score between the two cohorts: 4.7 for the DC and 5.3 for the VC. However, 0.6 point does not seem a clinically relevant difference, although the difference is statistically significant (P ¼ .005). In both cohorts, there was a preponderance of group 2 patients (Table V) . Once the four risk-specific survival curves were obtained, we tested whether there was any difference from their counterparts within the DC (Fig 3) . In all four comparisons, we found no statistically significant difference between the cohorts.
DISCUSSION
Benefit of surgery plus BMT over medical treatment alone was demonstrated for asymptomatic carotid stenosis $60%, given a perioperative morbidity and This was attributed to both the improvement of BMT and the reduction in the number of smokers. Accordingly, at present, an excessively high number of asymptomatic CEA or CAS procedures is probably needed to prevent a single ischemic event, with an obvious lack of cost-effectiveness. 12 Despite a growing awareness of the importance of selecting patients who will most likely benefit from CEA, no clear selection parameters have been defined, and this has led to huge discrepancies in the relative weight of asymptomatic carotid disease in national CEA registries among different countries, such as Sweden (about 10%) 13 and the United States (>90%). 14 In an ongoing effort to find a clear strategy for selection of asymptomatic patients, several factors are identifiable as indicators of a "higher risk" for evolution toward a symptomatic disease. It is general common sense that a stenosis whose degree shows a clear progression should be considered less stable than a lesion unchanged over the years. 15 
Fig 3.
Intercohort comparison of the group-specific estimated survival curves, divided by risk category. DC, Derivation cohort; VC, validation cohort.
The presence of multiple risk factors is predictive of increased cardiovascular risk and should be considered in the selection process: current smokers, uncontrolled hypertension, dyslipidemia, and diabetes. In particular, diabetes is known to carry a higher risk for development of symptoms. Because BMT plays a central role in the prevention of symptoms, the lack of adherence to therapy in an asymptomatic condition is another barrier that must be taken into account; intolerance to statins was recorded in up to 30% of the patients in international registries. 16 Moreover, there is intense research in the field of imaging that is aiming to identify plaques at high risk of embolization (type VI according to the American Heart Association classification); magnetic resonance angiography and computed tomography angiography features have been codified, 17,18 but they are far from reaching daily clinical practice. 19 Similarly, biomarkers have been developed that are increased in blood specimens from patients affected by carotid atherosclerotic lesions at high risk for stroke. 20 Among these, lipoprotein-associated phospholipase A 2 is the one that has the most promising results, 21 but again, its routine use is yet to be established. For the time being, exclusion of patients with short life expectancy who are less likely to have the time to reach a real benefit from CEA seems the most practical and less resource-consuming approach. In this study, we assessed postprocedural survival of our population of patients to analyze how many died before 5 years and which factors may affect long-term survival. No specific selection process was applied among candidates for carotid surgery in the three medical centers, except for a preoperative medical examination and other clinical tests. Although the process we followed was not standardized, we observed a remarkable 85% overall survival at 5 years for both DC and VC. At 1 year, the VC presented a slightly lower survival compared with the DC (96.5% vs 98.9%), and the difference might be attributed to the higher prevalence of patients with CAD in this cohort.
Other papers in the past have aimed to support clinicians in the selection of patients, proposing predictive scores based on survival likelihood. Five-year survival in our cohort (84.7%) was slightly higher than that reported by Wallaert et al 22 There is a general and uniform consensus of considering octogenarians and poor renal function (not to mention patients on dialysis) the strongest predictors of death before 5 years. 25 A few discrepancies among factors identified in these studies have also emerged. Lack of some factors in our series may be due to different treatment protocols, as for neck irradiation, 23 a category of patients that we treat exclusively with CAS, or to gap in data collection, as for contralateral ICA stenosis. 22 Our study presents limitations. Most data were retrospectively collected and remained incomplete for some factors (ie, contralateral stenosis). DC and VC differ for the proportion of CAD patients, probably because there is no cardiac surgery in the first hospital. The 16% difference in statin use is attributable as well to a higher proportion of well-recognized atherosclerotic patients among the VC hospitals. Conversely, dialysis patients are represented only in the DC. Finally, we have no data about patients who were refused surgery in the same period (possible control group).
In our view, this and other survival scores should never be used with an absolute cutoff for exclusion of asymptomatic patients from surgery. Rather, they should ideally support the decision process together with all other available information (degree of stenosis, disease progression, plaque morphology and composition, anesthesiology risk) of vascular surgeons and other physicians in facing patients for whom the best therapeutic option has to be chosen. For such reasons, we intentionally did not indicate any threshold to follow rigidly.
CONCLUSIONS
Our paper shows that it is possible to predict postoperative survival among candidates for CEA for asymptomatic stenosis through the application of a simple scoring system derived from our cohort and then validated on an external cohort of patients (Fig 4) . This tool (six variables) together with other clinical variables can help identify patients who will likely survive long enough to experience the benefits of surgery. 
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